《新股消息》據報瑞派寵物醫院管理年內來港上市 籌最多5億美元
據《IFR》引述知情人士指,內地連鎖寵物醫院集團瑞派寵物醫院管理計劃來港上市,目標籌集約3億至5億美元,預期最快今年底進行首次公開發售(IPO),將由股東高盛負責是次上市準備工作。
官網資料顯示,該公司成立於2012年,總部位於天津,目前轄下門店超過300家,每年接診量逾200萬宗,提供寵物門診、中獸醫專科、異寵專科門診、寵物食品用品銷售、健康管理、美容洗浴、行爲訓練及寄養等服務。
瑞派寵物醫院於2019年底宣佈完成C輪融資,引入瑪氏寵物護理、瑞普生物、華泰新產業基金、美國高盛集團以及越秀產業基金等投資者,估值達到70億元人民幣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.